Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners

Core Insights - GHO Capital Partners and Ampersand Capital Partners have successfully completed the acquisition of Avid Bioservices for approximately $1.1 billion, marking GHO's first public to private deal [1][4][7] - Avid Bioservices specializes in biologics Contract Development and Manufacturing Organization (CDMO) services, providing full lifecycle capabilities from concept to commercial supply [2][9] - The acquisition aims to leverage GHO and Ampersand's expertise in the CDMO sector to support Avid's growth, enhance service offerings, and expand geographic reach [3][4][10] Company Overview - Avid Bioservices has made significant investments in its state-of-the-art facilities and expertise in bioprocess optimization, analytical testing, and regulatory compliance, positioning itself as a leader in the biopharmaceutical development and manufacturing sector [2][9] - The company offers a comprehensive range of services, including CGMP clinical and commercial manufacturing, bulk packaging, and regulatory submissions support, with over 30 years of experience in producing biologics [9] Investment Strategy - GHO Capital's strategy focuses on expanding technological capabilities and supporting transatlantic expansion across the CDMO value chain, from early-stage development to commercial manufacturing [3] - Ampersand Capital Partners, with $3 billion in assets under management, is dedicated to growth-oriented investments in the healthcare sector, leveraging its private equity and operating experience to build value [10]